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ABSTRACT 
 
Background:  Testosterone levels in men decline with age and low testosterone levels 
or hypogonadism can cause multiple negative effects and symptoms.  Studies have 
shown that exogenous testosterone replacement therapy at physiological levels has a 
number of beneficial and protective effects on mood, libido, strength, lean body mass, 
bone health and cardiovascular health.  One of the many cardiovascular benefits of 
testosterone therapy is its action as a vasodilator and effect on angina and exercise 
induced myocardial ischemia.  This purpose of this paper is to review the effects of 
exogenous testosterone therapy in eugonadal and hypogonadal men with chronic stable 
angina.  All evidence will be evaluated using the GRADE method.  
 
Method:  An exhaustive search of available medical literature was conducted through 
Medline, EBM, and CINHAL databases. 
   
Results: Two randomized controlled trials were reviewed along with the outcome of time 
to 1mm ST segment depression on treadmill exercise testing.  Both studies showed 
statistically relevant improvements in time to 1mm ST segment depression as well as 
improvements in total exercise time.  Impact on overall quality of life also showed 
significant improvement verses placebo.  Both studies showed an insiginificant increase 
in Hematocrit and PSA levels but all within normal physiologic ranges.  No other 
adverse effects were seen.   
 
Conclusion: Exogenous testosterone replacement therapy improves overall exercise 
time and time to 1mm ST segment depression in male eugonadal and hypogonadal 
patients with angina and myocardial ischemia. Overall GRADE of evidence was 
considered to be moderate.   
 
Keywords:  Hypogonadism, testosterone replacement therapy, male, angina, 
myocardial ischemia 
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INTRODUCTION 
Background 
Hypogonadism, also called androgen deficiency, is defined as a clinical 
syndrome that results from failure of the testes to produce physiological levels of 
testosterone, a major androgenic hormone synthesized and secreted by the Leydig cells 
of the testes  (Costanzo, 2006).  There are two causes of hypogonadism with primary 
hypogonadism being usually age related and due to Leydig cell dysfunction where the 
testicles fail to produce adequate amounts of testosterone resulting in low serum 
testosterone levels and increased production of luteinizing hormone and follicle-
stimulating hormone by the anterior pituitary gland and secondary hypogonadism which 
is a failure of the hypothalamic–pituitary unit to produce sufficient levels of LH/FSH 
resulting in low testosterone levels with low LH/FSH.   LH and FSH are produced by the 
anterior pituitary and signal the testis to produce testosterone.   (Calof, Singh, Lee, 
Kenny, Urban, Tenover & Bhasin,  2005) 
Symptoms of hypogonadism include: incomplete or delayed sexual development, 
decreased sexual desire/libido, decreased spontaneous erections, breast discomfort, 
gynecomastia, loss of axillary and pubic hair, very small or shrinking testes (< 5cm), low 
or zero sperm count, height loss, low trauma fractures, low bone mineral density, hot 
flushes and sweats, decreased energy, motivation, initiative and self confidence, feeling 
sad, blue and depressed mood, poor concentration and memory, sleep disturbances, 
increased sleepiness, mild anemia, decreased bulk and strength, increased body fat 
and body mass index, decreased physical or work performance (Stanworth & Jones, 
2008). 
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Physiologic levels of total testosterone according to reference laboratory levels 
are between 300ng/dL and 1000ng/dL. Bhasin, Cunningham, Hayes, Matsumoto, 
Snyder & Montori (2006) identify levels below 300ng/dL as the threshold for defining 
hypogonadism.  The conventional testosterone unit used in the United States is 
measured  in ng/dl.   The international system of units (SI Units) used abroad are 
measured in nmol/L and normal testosterone levels are  between 7.5-37 nmol/L.  
Recent studies have shown that 5.5% of a random sample of men age 30-79 had 
testosterone levels  below 300ng/dL and at least one symptom of hypogonadism (Hall, 
Esche, Araujo, Travison, Clarek & McKinlay, 2008).  According to the Baltimore 
Longitudinal Study on Aging (2006), the prevalence of hypogonadism increases with 
age rising from less than 10% in men under 49 years old to 12% of men in their 50’s to 
19% of men in their 60’s, 28% of men in their 70’s and 49% of men in their 80’s.  There 
is a diurnal variation in serum testosterone levels with peak levels seen in the morning 
following sleep.  Samples measuring testosterone levels should always be taken in the 
morning before 11am to allow for standardization.  (Stanworth, Jones, 2008). 
 Other conditions causing hypogonadism include radiation therapy, use of 
medications with antiandrogen properties such as glucocorticoids, ketoconazole, 
opioids, and marijuana, end stage renal disease, maintenance dialysis, moderate to 
severe chronic obstructive pulmonary disease, HIV related weight loss, infertility, 
osteoporosis, dyslipidemia, hereditary hemochromatosis, Type II Diabetes 
Mellitus,metabolic syndrome, tobacco use and obesity (Wald, Meacham, Ross, & 
Niederberger, 2006).  
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Exogenous testosterone therapy with low dose physiological replacement to 
stabilize testosterone levels within the physiological range has become a focus as of 
late because of its postulated anti-inflammatory and vasodilatory properties as well as 
ability to  decrease cardiac afterload and increase angina threshold in patients with 
chronic stable angina.  Stable angina is a dull aching retrosternal chest pain aggravated 
by exercise and relieved by rest which has been linked to the narrowing of the arteries 
in the heart caused by coronary artery disease.  (Choi, McLaughlin, 2007). Narrow 
arteries reduce the availablity of blood to the heart, this reduced blood flow to the heart 
is also known as myocardial ischemia.    Ischemia becomes a problem during exercise, 
when extra blood and oxygen are needed by the body.  When patients with angina 
exercise they can experience severe pain in the vessels supplying the heart (Cornoldi, 
Caminiti, Marazzi, Vitale, Patrizi, Volterrani & Rosano, 2010).  Myocardial Ischemia can 
be identified by horizontal ST segment depression on the electrocardiogram during 
exercise treadmill testing.  
  Other benefits of exogenous testosterone therapy include improvement in 
sexual function, libido, increased sense of well being, improved mood, increased 
energy, better sleep, antidepressant effect, increase in muscle mass, strength, and 
bone mineral density (Bhasin, 2006). 
Side effects of physiological dose exogenous testosterone therapy can include 
polycythemia, increased hemoglobin and hematocrit,  detection of subclinical prostate 
cancer, growth of metastatic prostate cancer, as well as increased acne and hair growth 
(Morales, 2001).   
Purpose of the Study 
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The purpose of this paper is to perform a systematic review of the literature on the use 
of exogenous testosterone replacement therapy for improvements in cardiovascular 
outcomes in the adult male using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) tool developed by the GRADE Working Group.  
(Guyatt, Oxman, Vist, Kunz, Falck-Ytter, Alonso-Coello & Scheunemann, 2008)  
METHODS 
An extensive literature search was performed using EBM, Medline, and CINHAL  
These databases were accessed through the Pacific University Library system. The 
following keywords were searched individually and in combination: hypogonadism, 
testosterone testosterone replacement therapy, angina and myocardial ischemia.  The 
search was limited to human subjects, males, the English language and to articles 
published since 2000.  The initial results included 52 articles.  Men with low or low 
normal testosterone levels and treated with any testosterone formulation were included 
as were comorbidities of hypertension, diabetes, and hypercholesterolemia.  Articles 
that did not investigate the cardiovascular effects of testosterone and time to ST 
segment depression on ECG treadmill testing were excluded.  Review articles, and 
systematic reviews were excluded.  Also excluded were any studies examining patients 
with secondary causes of hypogonadism purely as a result of  surgery or radiation 
treatment due to prostate cancer.  This resulted in two randomized controlled trial 
studies for the final systematic review.   
RESULTS  
A total of two randomized control studies were analyzed for this review.  A total of 
60 patients were recruited for both studies. The first study reviewed, (English, Steeds, 
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Jones, Diver & Channer, 2000)  included 50 eugonadal adult males with average age of 
62 and average testosterone level of 13.55 nmol/L. This study examined the clinical 
effects of long term low dose androgens in men with angina.  The second study 
reviewed, (Malkin, Pugh, Morris, Kerry, Jones & Channer, 2003) included 10 
hypogonadal adult males with an average age of 60.8 with an average testosterone 
level of 4.2 nmol/L.  This study measured the effects of testosterone replacement on 
ischaemic threshold in hypogonadal men with angina.    Patients in both studies were 
on antianginal medications during the trial but were not allowed to make medication 
changes 4 weeks prior to treadmill testing.  They were also asked not to use glyceryl 
trinitrate six hours prior to treadmill testing.  Patients were included in both studies if 
they had confirmed coronary artery disease (>70% stenosis of a major coronary artery 
at coronary angiography), previous proven myocardial infarction, symptoms of angina 
pectoris, male sex and age greater than 18.  Malkin et al., (2003) included only patients 
with a clinical indication for testosterone therapy, eg. hypogonadal males.  Both studies 
included patients with various co-morbid conditions of hypertension, diabetes mellitus, 
family history of myocardial ischemia, current smokers, and hypercholestermia in both 
the testosterone and placebo groups at presentation.  Exclusion criteria for both studies 
were prostate specific antigen concentration above normal range or any other 
contraindication to androgen therapy.  They were also excluded if they had left main 
stem artery stenosis, a coronary or cerebrovascular event or taking other trial drugs 
within the preceding three months, severe hypertension ( BP > 180/114mg/Hg), 
significant arrhythmias or ECG abnormalities precluding ST-segment analysis on a 
treadmill.  Patients in both studies had their baseline total testosterone levels measured 
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between 8am and 9:30 am which are peak testosterone levels for the adult male as 
testosterone levels follow a circadian rhythm ( Caminiti et al., 2009) 
Interventions for English et al., (2000) included 5mg of transdermal testosterone 
via two 2.5mg patches placed nightly, Andropatch.  Malkin et al., (2003)  included 
100mg intramuscular testosterone given by deep intramuscular injection to the buttock 
every two weeks.  Comparison for both groups was placebo without active testosterone.  
Final outcome and primary endpoint for both groups was time to 1-mm ST- segment 
depression with treadmill testing.  Quality of life was also measured in both studies.  
English et al., (2000) measured total testosterone as well as time to 1-mm ST- segment 
depression for both the active and placebo groups in  at baseline, week 6, and week 14.  
Malkin et al., (2003) only measured outcomes at baseline and after 4 weeks for the 
active and placebo groups.  English et al., (2000) revealed total testosterone levels of 
13.55 nmol/L at baseline, 22.34 nmol/L at week 6 and 18.57nmol/L at week 14.  Mean 
time to 1mm ST-segment depression in the testosterone group was 309 seconds at 
baseline, 343 seconds at week 6 and significantly greater by week 14 (P < 0.05) at 361 
seconds.  Mean time to 1mm ST-segment depression increased in both the placebo 
and testosterone groups but the increase in the active testosterone group was greater 
than the placebo group.  Results in Malkin et al., (2003) revealed total testosterone 
levels of 4.39 nmol/L at baseline and 9.19 nmol/L at 4 weeks.  Mean time to 1mm ST- 
segment depression in the testosterone group was 318 seconds at baseline and 399 
seconds at 4 weeks (P< 0.0001) Compared with placebo, the testosterone group had a 
greater increase in mean time to 1mm ST- segment depression by 81 seconds vs 7.2 
seconds in the placebo group.  
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Limitations for both studies included the eugonadal population in English et al., 
(2000)  vs. hypogonadal population in Malkin et al., (2003).  Measurements were not 
performed during the same weeks of therapy and therapy length was also different 
between both studies as well as variation in types of testosterone, delivery and dosing.  
The sample size in Malkin et al., (2003) was small at only 10 patients.   
English et al., (2000) concluded that low dose supplemental testosterone 
treatment in men with chronic stable angina reduced exersice induced myocardial 
ischemia and time to ST segment depression.  Adverse effects showed no significant 
change in hemoglobin or PSA in either the active or placebo groups.   
Malkin et al., (2003) concluded that testosterone replacement therapy in 
hypogonadal men delayed the time to ischemia as measured by ST segment 
depression.  Adverse effects included a slight but insignificant rise in PSA levels in the 
active group.  Both studies showed improvements in mood and quality of life.   
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DISCUSSION 
These studies both demonstrate that exogenous testosterone supplementation in 
men with chronic stable angina improves time to myocardial ischemia over placebo.  In 
both studies by Malkin et al.(2003) and English et al. (2000) improvements in time to 
ischemic threshold improved by 14%  and 22% respectively compared with placebo. 
Numerous other studies have attributed this improvement in ischemia  to  the 
vasodilatory effects of testosterone (Webb, Elkington, Draidly, Keenan, Pennell & 
Collins, 2008) and ( Pugh, Jones & Channer, 2003)  
 
Testosterone was also associated with major improvements in mood and quality 
of life.  The Malkin et al. (2003) study measured this by scores on the ADAM test which 
stands for androgen deficiency in the adult male.  This test consists of 10 true/false 
questions regarding  current health status.  Lower scores indicate better quality of life.  
Malkin, 2003 showed major improvements in mood and hypogonadal symptoms with 
ADAM decreasing by 3 points vs O points with placebo.  English et al., (2000) 
measured quality of life through the Raw SF-36 test.    This test looks at 8 domains 
covering functional status, well-being and overall evaluation of health.  Each domain is 
given a numerical score.  A high numerical score, or positive change in score indicates 
an improvement in well being or overall quality of life.  Patients showed an improvement 
in all 8 domains after 14 weeks of testosterone therapy.  The greatest improvements  
were in  pain perception and role limitation resulting from physical problems.    
There were no serious side effects in either studies.  Studies have shown than 
testosterone therapy can cause an overall increase in both PSA  and hematocrit levels.  
 12
Although there was an increase in PSA levels in both studies, there was no evidence of 
increase in prostate symptoms such as difficulty or frequency of urination.  Studies have 
shown that this is a benign and clinically insignificant elevation of PSA levels and could 
correlate with the advanced  age of the study participants and the fact that PSA levels 
do increase with age (Legros et al., 2009).  Despite the clinically insignificant elevations 
in PSA levels, Nieschlat (2005), recommends all patients being treated with 
testosterone therapy be screened with both PSA and digital rectal exam every 3 months 
while on testosterone therapy.  The increase in hematocrit seen in both studies is due to 
testosterones effect on elevating red blood cell mass and stimulation of  bone marrow 
hematopoiesis  causing polycythemia. (Basaria, 2007).  The average increase in 
hematocrit among men treated with testosterone therapy is 7%.  (Tenover,1999).  The 
elevation in hematocrit in both studies was still under the cutoff of 54% which is the 
point that testosterone therapy should be discontinued.  (Bhasin et al., 2006).  
Both studies had limitations which were evaluated using the GRADE system.  
GRADE stands for Grading of Recommendations assessment, development and 
evaluation.  This system is used to determine the quality of evidence presented in 
studies.  There are four grade categories according to Guyatt, (2008).   
1) High= further research is very unlikely to change our confidence in the 
estimate of effect. 
2) Moderate= further research is likely to have an important impact on our     
confidence in the estimate of the effect and may change the estimate. 
3) Low= further research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change the estimate. 
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4) Very low= any estimate of effect is very uncertain.  
The studies were given an overall grade of moderate.  GRADE was decreased from 
high to moderate due to the quality of the Malkin et al., (2003)study.  He had a small 
sample size of only 10 participants, it was a single blind study and he only measured 
testosterone therapy for a short period of only four weeks compaired to fourteen weeks 
in the English et al., (2000) study.    The researchers were not blinded to the treatment 
and placebo groups.  Malkin et al., (2003) states this was accounted for by use of the 
Marquette  ECG data recording software that eliminated observer bias of the ECG 
results during treadmill testing.   
Study limitations include different active treatment time lengths, different routes 
of testosterone admisistration and different baseline levels of testosterone between both 
studies.    Previous studies have shown the effects of testosterone therapy on ischemic 
symptoms are greater  in hypogonadal men verses eugonadal men. (Mathur et al., 
2009).  I believe these differences are only limitations and do not effect the overall 
GRADE of the studies.   
Conclusion 
The effects of testosterone therapy have shown promising evidence in the anti-
ischemic  and vasodilatory effects on myocardial tissue and overall cardiovascular 
health (Caminiti et al., 2009).  Both studies showed improvements in time to ST 
segment depression with exercise and overall increased exercise time as well as quality 
of life improvement with  no significant side effects identified in either study.  Based on 
these studies I feel that testosterone therapy would improve overall health and well 
being in the adult male population and exogenous testosterone therapy administered in 
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the physiologic range would be beneficial for older adult males with  hypogonadal 
symptoms and low serum total testosterone levels.  Additional randomized controlled 
studies with a larger study population are needed to provide higher quality evidence of 
the effects of testosterone therapy in hypogonadal males.   
 
 
 15
REFERENCES 
Basaria, S., Dobs, A.S.  (2001). Hypogonadism and androgen replacement therapy in 
elderly men.  The American Journal of Medicine, 110, 563-572. 
 
Basaria, S., & Dobs, A.S.  (2007).  Testosterone Making an Entry Into the 
Cardiometabolic World.  Circulation, 116, 2658-2661. 
 
Bhasin, S., Cunningham, G.R., Hayes, F.J., Matsumoto, A.M., Snyder, P.J., Swerdloff, 
R.S., & Montori, V.J.,  (2006)  Testosterone therapy in adult men with androgen 
deficiency syndromes:  an Endocrine Society clinical practice guideline.  The 
Journal of Clinical Endocrinology and Metabolism, 91, 1049-57. 
 
Calof, O.M., Singh, A.B., Lee, M.L., Kenny, A.M., Urban, R.J., Tenover, J.L., & Bhasin,      
S.  (2005).  Adverse Events Associated With Testosterone Replacement in 
Middle-Aged and Older Men:  A Meta- Analysis of Randomized, Placebo-
Controlled Trails.  Journal of Gerontology, 60, 1451-1457.  
 
Caminiti, G., Volterrani, M., Iellamo, F., Marazzi, G., Massaro, R., Miceli, M., …Rosano, 
M.C.  (2009).  Effect of Long-Acting Testosterone Treatment on Functional 
Exercise Capacity, Skeletal Muscle Performance, Insulin Resistance, and 
Baroreflex Sensitivity in Elderly Patients With Chronic Heart Failure:  A Double-
Blind, Placebo-Controlled, Randomized Study.  Journal of the American College 
of Cardiology, 54, 919-927.  
 
Choi, B.G., & McLaughlin, M.A.  (2007).  Why Men’s Hearts Break:  Cardiovascular 
Effects of Sex Steroids.  Endocrinology and Metabolism Clinics of North America, 
36, 365-377.  
 
Costanzo, LS. Physiology Third Edition.  Philadelphia, PA:  Saunders Elsevier; 2006 
 
Cornoldi, A., Caminiti, G., Marazzi, G., Vitale, C., Patrizi, R., Volterrani, M., …Rosano, 
G.  (2010).  Effects of chronic testosterone administration on myocardial 
ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients 
with coronary artery disease.  International Journal of Cardiology, 142, 50-55. 
 
English, K.M., Steeds, R.P., Jones, T.H., Diver, M.J., & Channer, S. (2000).  Low- Dose 
Transdermal Testosterone Therapy Improves Angina Threshold in Men with 
Chronic Stable Angina:  A Randomized, Double- Blind, Placebo- Controlled 
Study.  Circulation, 102, 1906-1911.  
 
Guyatt, G.H., Oxman, A.D., Vist, G., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P. & 
Schunemann, H.J., for the GRADE Working Group (2008). Rating quality of 
evidence and strength of recommendations GRADE: an emerging consensus on 
rating quality of evidence and strength of recommendations.  
BMJ ;336:924-926  
 16
 
Hall, S.A., Esche, G.R., Araugo, A.B., Travison, T.G., Clarek, R.V., & McKinlay (2008).  
Correlates of low testosterone and symptomatic androgen deficiency in a 
population based sample.  Journal of Clinical Endocrinology and Metabolism, 93, 
3870-3877. 
 
Legros, J.J., Meuleman, E.J.H., Elbers, J.M.H., Geurts, T.B.P., Kaspers, M.J., & 
Bouloux, P.M.G.  (2009).  Oral testosterone replacement in symptomatic late-
onset hypogonadism:  effects of rating scales and general safety in a  
randomized placebo-controlled study.  European Journal of Endocrinology, 160, 
821-831.  
 
Malkin, C.J., Pugh, P.J., West, J.N., Van Beek, J.R. & Jones, T.H. (2006).  Testosterone 
therapy in men with moderate severity heart failure:  a double-blind randomized 
placebo controlled trial.  European Heart Journal, 27, 57-64.  
 
 
Malkin, C.J., Pugh, P.J., Morris, P.D., Kerry, K.E., Jones, R.D., Jones, T.H., & Channer, 
K. S. (2003).  Testosterone replacement in hypogonadal men with angina 
improves ischemic threshold and quality of life.  Heart, 90, 871-876. 
 
Malkin, C.J., Pugh, P.J., West, J.N., Van Beek, J.R. & Jones, T.H. (2006).  Testosterone 
therapy in men with moderate severity heart failure:  a double-blind randomized 
placebo controlled trial.  European Heart Journal, 27, 57-64.  
 
 
Mathur, A., Malkin, C., Saeed, B., Muthusamy, R., Jones, T.H., & Chamber, K.  (2009) 
European Journal of Endocrinology, 161, 443-449. 
 
Morales, A.  (2001).  Androgen Replacement Therapy and Prostate Safety.  European 
Urology, 41, 113-120.  
 
National Institute on Aging (2006). The Baltimore Longitudinal Study on Aging. The 
National Institute of Health. 
 
Pugh, P.J., Jones, T.H. & Channer, K.S., (2003).  Acute hemodynamic effects of 
testosterone in men with chronic heart failure.  European Heart Journal, 24, 909-
915.  
 
Rosano, G.M., Leonardo, F., Pagnotta, P., Pelliccia, F., Panina, G., Cerquetani, E., 
…Chierchia, S.L. (1999).  Acute Anti-Ischemic Effect of Testosterone in Men 
With Coronary Artery Disease.  Circulation, 99, 1666-1670. 
 
 
Rosano, G.M.C., Sheiban, I., Massaro, R., Pagnotta, P., Marazzi, G., Vitale, C., … Fini, 
M.  (2007).  Low testosterone levels are associated with coronary artery disease 
 17
in male patients with angina.  International Journal of Impotence Research, 19, 
176-182. 
 
 
Stanworth, R.D., & Jones, T.H.  (2008).  Testosterone for the aging male; current 
evidence and recommended practice.  Clinical interventions in aging, 3, 25-44.  
 
Tenover, J.L. (1999).  Testosterone replacement therapy in older adult men.  
International Journal of Andrology, 22, 300-306. 
 
Wald, M., Meacham, R.B., Ross, L.S. & Niederberger, C.S.  (2006).  Testosterone 
Replacement Therapy for Older Men.  Journal of Andrology, 27, 126-130. 
 
Webb, C.M., Elkington, A.G., Kraidly, M.M., Keenan, N., Pennell, D.J., & Collins, P.  
(2008).  Effects of Oral Testosterone Treatment on Myocardial Perfusion and 
Vascular Function in Men with Low Plasma Testosterone and Coronary Heart 
Disease.  American Journal of Cardiology, 101, 618-624. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 18
 
 
 
 
 
 
 
 
 
 
 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 19
APPENDIX A 
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patients.  
Time to 
Angina 
threshold/ 1 
mm ST- 
segment 
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treadmill 
testing 
2 RCT 
(60) 
Increase in 
time to 
1mm ST 
segment 
depression 
High -1 0 0 0 0 0 0 0 Moderate  
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APPENDIX B 
 
Table 1: Malkin et al., (2003) Testosterone replacement in hypogonadal ment with angina 
improves ischaemic threshold and quality of life.  
 
 Placebo   100mg IM 
Testosterone 
every 2 
weeks 
  
Variable Baseline 4 weeks pValue Baseline 4 weeks p Value 
Age (years) 60.8 +/-4.6   60.8 +/- 4.6   
Time to 
1mm ST 
depression 
(seconds) 
345 352 0.492 318 399 <0.0001 
Prostate 
Specific 
Antigen 
(ug/l) 
1.01+/- 1.3   1.01+/- 1.3   
Hemoglobin 
(g/l) 
148 149 0.81 147 150 0.02 
Total 
Testosterone 
(nmol/l) 
5.55 5.5 0.94 4.39 9.19 0.02 
ADAM 
Score 
6 6 0.5 7 4 0.007 
ADAM-androgen deficiency in the adult male screen score. (Negative change in score = 
improvement in health perception. 
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APPENDIX C 
 
Table 2:  English et al., (2000) Low Dose Transdermal Testosterone Therapy Improves 
Angina Threshold in Men with Chronic Stable Angina:  A Randomized, Double-Blind, 
Placebo- Controlled Study 
 
 Placebo   5mg 
Testosterone 
patch placed 
nightly 
   
Variable Baseline 6 
weeks 
14 
weeks 
Baseline 6 weeks 14 
weeks 
p Value 
Age (years) 62 +/- 2   62 +/- 2    
Time to 1mm 
ST depression 
(seconds) 
267 +/- 
25 
284 +/- 
23 
292 +/- 
24 
309 +/- 27 343 +/- 
26 
361 +/- 
22 
0.02 
Total 
Testosterone 
(nmol/l) 
12.38 +/- 
0.72 
11.35 
+/- 
0.76 
12.23 
+/-0.89 
13.55 +/-0.78 22.34+/-
1.19 
18.57+/-
1.6 
<0.0001 
Raw SF-36 
Score 
   50.6 +/-4 53.8+/-
5.5 
53.1+/-
5.2 
0.43 
SF-36 Short Form quality of life questionnaire (positive change in score = improvement 
in health perception.) 
 
 
 
 
 
 
 
 
 
 
